Page 11 - Stephen Schultz News Today

COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I study showing that its COMP360 psilocybin had no clinically-relevant negative effect on cognitive function, when administered to healthy adult volunteers with support from specially trained therapi...

Operator Good day, ladies and gentlemen, and welcome to the COMPASS Pathways first-quarter 2021 conference call. [Operator instructions]. As a reminder, this call is being recorded. I would now Like to introduce your host for todays conference, Stephen Schultz, senior vice president of investor relations. You may begin. Senior Vice President, Investor Relations Thank you, operator, and welcome all of you, and thank you for joining us today for our first-quarter 2021 results call. Again, my name...

May 13, 2021 Neil Schultz, 58 of Rochester, formerly of Weirton, West Virginia passed away on Friday, May 7, 2021 at his residence. Born in Weirton, he was a son of the late Edward and Barbara Schultz. A graduate of Brooke High School, Neil was a member of the track and cross- country teams. He then attended West Liberty University. Neil enjoyed listening to music and playing his guitar, fishing and boating. He was an active member of the Ashes to Life Ministries in Beaver Falls and their musi...

May 13, 2021 Neil Schultz, 58 of Rochester, formerly of Weirton, West Virginia passed away on Friday, May 7, 2021 at his residence. Born in Weirton, he was a son of the late Edward and Barbara Schultz. A graduate of Brooke High School, Neil was a member of the track and cross- country teams. He then attended West Liberty University. Neil enjoyed listening to music and playing his guitar, fishing and boating. He was an active member of the Ashes to Life Ministries in Beaver Falls and their musi...

(0) Highlights: New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder Two further US patents granted Equity financing raises gross proceeds of $144 million Phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD) on track to report data by end of 2021 Wayne J Riley MD joins Board of Directors and Anne Benedict is appointed Chief People ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. COMPASS Pathways announces pricing of public offering COMPASS Pathfinder Ltd.April 30, 2021 GMT     London, UK, 30 April 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of its public offering of 4,000,000 American Depositary Sh...

COMPASS Pathfinder Ltd.: COMPASS Pathways announces pricing of public offering London, UK, 30 April 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of its public offering of 4,000,000 American Depositary Shares ("ADSs") representing 4,000,000 ordinary shares at a public offering price of $36.00 per ADS for total gross proceeds...

COMPASS Pathways launches proposed public offering COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the launch of a proposed public offering of 4,000,000 American Depositary Shares each representing one ordinary share. Each of the ADSs is being offered by COMPASS. COMPASS expects to grant the underwriters a 30-day option to purchase up to an additional 600,000 … COMPASS Pathways plc (Nasda...

(0) Study concludes that psilocybin findings should be explored further in larger studies London, UK, April 15, 2021(NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD). The study was designed and conducted by a research team at Imperial College London, using COMPASSs COMP360 psilocybin. This was an exploratory, randomised, double-blind clinical study. Its aim was to compar...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. New England Journal of Medicine publishes exploratory study showing signals of positive ... COMPASS Pathfinder Ltd.April 15, 2021 GMT London, UK, April 15, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the  New England Journ...